Efficacy and safety of valsartan compared with enalapril at different altitudes

International Journal of Cardiology

Volumn 72, Issue 3, 2000, Pages 247-254

  Botero, R ^a   Matiz, H ^b   Maria E ^c   Orejarena, H ^d   Blanco, M ^d   Velez, J R ^b   Del Portillo, H ^b  

^a Clinica Medellin   (Colombia)

^b UNIVERSIDAD EL BOSQUE   (Colombia)

^c Instituto de Enfermedades Hepáticas y Digestivas   (Colombia)

^d HOSPITAL MILITAR CENTRAL   (Colombia)

Author keywords

Angiotensin II receptor blocker; AT1 antagonist; Enalapril; Essential hypertension; Indapamide; Valsartan

Indexed keywords

ENALAPRIL; INDAPAMIDE; VALSARTAN;

ADULT; AGED; ALTITUDE; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COUGHING; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ESSENTIAL HYPERTENSION; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORTHOSTATIC HYPOTENSION; OUTPATIENT CARE; POLYURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SWEATING; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; THORAX PAIN; URBAN AREA; URINE RETENTION; VERTIGO;

ADULT; ALTITUDE; ANTIHYPERTENSIVE AGENTS; COLOMBIA; ENALAPRIL; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; SAFETY; TETRAZOLES; VALINE;

EID: 0033975045     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(99)00194-1     Document Type: Article

References (27)

1. Sealey J.E., Laragh J.H. The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis. Brenner B.M., Laragh J.H. Hypertension. 1990;1287-1319 Raven Press Ltd, New York.
2. Sassano P., Chatelier G., Alhenc-Gelas F., Corvol P., Menard J. Antihypertensive effect of enalapril as first-step treatment of mild and moderate uncomplicated essential hypertension: evaluation by two method of blood pressure measurement. Am J Med. 77:1984;18-22.
3. nd ed Hypertension: pathophysiology, diagnosis and management. 1995;2861-2872 Raven Press, New York.
4. Verme-Gibboney C. Oral angiotensin converting enzyme inhibitors. Am J Health Syst Pharm. 54:1997;2689-2703.
5. Skidgel R.A., Erdoes E.G. The broad substrate specificity of human angiotensin I converting enzyme. Clin Exper Hypertension. A9:1987;243.
6. Ferner R.E., Simpson J.M., Rawlins M.D. Effects of intradermal bradykinin after inhibition of angiotensin converting enzyme. Br Med J. 294:1987;1119.
7. Israili Z.H., Hall W.D. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann Int Med. 117:1992;234-242.
8. Elliott W.J. Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects. Clin Pharmacol Ther. 60:1996;582-588.
9. Morice A.H., Brown M.J., Higenbottam T. Cough associated with angiotensin converting enzyme inhibition. J Cardiovasc Pharmacol. 13:1989;S59-S62.
10. Semple P.F., Herd G.W. Cough and wheeze caused by inhibitors of angiotensin-converting enzyme. New Engl J Med. 314:1986;61.
11. Webb D., Benjamin N., Collier J. Robinson B. Enalapril induced cough. Lancet. 2:1986;1094.
12. Oparil S., Dyke S., Harris F., Kief J., James D., Hester A., Fitzsimmons S. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther. 18:1996;797-810.
13. Criscione L., Bradley W.A., Bühlmayer P., Whitebread S., Glazer R., Lloyd P., Mueller P., de Gasparo M. Valsartan: preclinical and clinical profile of an antihypertensive angiotensin II antagonist. Cardiovasc Drug Rev. 13:1995;230-250.
14. Müller P., Cohen T., de Gasparo M., Sioufi A., Racine-Poon A., Howald H. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol. 47:1994;231-245.
15. Benz J., Oshrain C., Henry D., Avery C., Chiang Y.-T., Gatlin M. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol. 37:1997;101-107.
16. Black H.R., Graff A., Shute D., Stoltz R., Ruff D., Levine J., Shi Y., Mallows S. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin converting enzyme inhibitor, lisinopril. J Hum Hypertens. 11:1997;483-489.
17. Holwerda N.J., Fogari R., Angeli P., Porcellat C., Hereng C., Oddou-Stock P., Heath R., Bodin F. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypert. 14:1996;1147-1151.
18. Mallion J-M., Boutelant S., Chabaux P., Baguet J.-P., Muller M., Meilenbrock S., Heath R., Bodin F. Valsartan, a new angiotensin II antagonist: blood pressure reduction in essential hypertension compared with an angiotensin converting enzyme inhibitor, enalapril. Blood Press Monit. 2:1997;179-184.
19. Khalid M.E., Ali M.E., Ahmed E.K., Elkarib A.O. Pattern of blood pressures among high and low altitude residents of southern Saudi Arabia. J Hum Hypertens. 8:1994;765-767.
20. Rosa-Cusachs A. Pattern of blood pressure among high and low altitude residents of southern Saudi Arabia: Comment. J Hum Hypertens. 10:1994;765-769.
21. Mirrakhimov M.M. The treatment of hypertension by adaptation to high-altitude hypoxia. Kardiologgia. 32:1992;5-10.
22. Niazova Z.A., Batyraliev T.A., Aikimbaev K.S., Kudaiberdieva G.Z., Akgul F., Soodanbekova Y.K., Birand A. High altitude pulmonary hypertension: effects of captopril on pulmonary and systemic arterial pressures. J Hum Hypertens. 3Suppl:1996;S141-142.
23. Morrell N.W., Sarybaev A.S., Alikhan A., Mirrakhimov M.M., Aldashev A.A. ACE genotype and risk of high altitude pulmonary hypertension in Kyrghyz highlanders. Lancet. 353:1999;814.
24. Hanna J.M. Climate, altitude and high blood pressure. Hum Biol. 4:1999;553-582.
25. Milledge J.S. Angiotensin converting enzyme and hypoxia. Bull Eur Physiopathol Respir. 20:1984;481-485.
26. Wolfel E.E., Selland M.A., Mazzeo R.S. Reeves JT: Systemic hypertension at 4,300 m is related to sympathoadrenal activity. J Appl Physiol. 76:1994;1643-1650.
27. Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee. Summary of the 1993 World Health Organisation-International Society of Hypertension guidelines for the management of mild hypertension. Br Med J 1993; 307: 1541-1546.